| Stephen Samuel Weigt, MD | |
|
200 Med Plz, Suite 365, Los Angeles, CA 90095-0001 | |
| (310) 825-8061 | |
| Not Available |
| Full Name | Stephen Samuel Weigt |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 23 Years |
| Location | 200 Med Plz, Los Angeles, California |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063617116 | NPI | - | NPPES |
| 00A828710 | Medicaid | CA |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ronald Reagan Ucla Medical Center | Los angeles, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| The Regents Of The University Of California | 1355248584 | 1177 |
News Archive
Noting the WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday issued a joint statement calling for an additional $1.6 million a year to fight tuberculosis (TB) in low- and middle-income countries, GlobalPost's "Global Pulse" blog examines the global impact of childhood TB, writing, "While health officials did not single out the devastating impact of the disease on children ... WHO estimates that at least 500,000 children contract TB each year and that 70,000 die from the disease, largely in Asia and Africa."
Johns Hopkins researchers today published new evidence refuting the long-held scientific belief that the gut nerve cells we're born with are the same ones we die with.
Anacor Pharmaceuticals announced today that the University of California San Francisco (UCSF) has been awarded $718,136 in funding from the National Institutes of Health (NIH) to discover and optimize novel oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals. The NIH grant provides support for the period beginning September 30, 2011 and ending September 29, 2012.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
› Verified 7 days ago
| Entity Name | The Regents Of The University Of California |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235107566 PECOS PAC ID: 1355248584 Enrollment ID: O20031223000439 |
News Archive
Noting the WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday issued a joint statement calling for an additional $1.6 million a year to fight tuberculosis (TB) in low- and middle-income countries, GlobalPost's "Global Pulse" blog examines the global impact of childhood TB, writing, "While health officials did not single out the devastating impact of the disease on children ... WHO estimates that at least 500,000 children contract TB each year and that 70,000 die from the disease, largely in Asia and Africa."
Johns Hopkins researchers today published new evidence refuting the long-held scientific belief that the gut nerve cells we're born with are the same ones we die with.
Anacor Pharmaceuticals announced today that the University of California San Francisco (UCSF) has been awarded $718,136 in funding from the National Institutes of Health (NIH) to discover and optimize novel oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals. The NIH grant provides support for the period beginning September 30, 2011 and ending September 29, 2012.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen Samuel Weigt, MD 5767 W Century Blvd, Suite 200, Los Angeles, CA 90045-5632 Ph: (310) 301-8708 | Stephen Samuel Weigt, MD 200 Med Plz, Suite 365, Los Angeles, CA 90095-0001 Ph: (310) 825-8061 |
News Archive
Noting the WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria on Monday issued a joint statement calling for an additional $1.6 million a year to fight tuberculosis (TB) in low- and middle-income countries, GlobalPost's "Global Pulse" blog examines the global impact of childhood TB, writing, "While health officials did not single out the devastating impact of the disease on children ... WHO estimates that at least 500,000 children contract TB each year and that 70,000 die from the disease, largely in Asia and Africa."
Johns Hopkins researchers today published new evidence refuting the long-held scientific belief that the gut nerve cells we're born with are the same ones we die with.
Anacor Pharmaceuticals announced today that the University of California San Francisco (UCSF) has been awarded $718,136 in funding from the National Institutes of Health (NIH) to discover and optimize novel oxaboroles as antimalarial drugs in collaboration with Anacor Pharmaceuticals. The NIH grant provides support for the period beginning September 30, 2011 and ending September 29, 2012.
X-Chem, Inc. today announced the signing of a multi-year collaborative agreement with Roche to apply X-Chem's proprietary platform to the rapid discovery of drug candidates against several of Roche's high-value therapeutic targets.
A new comprehensive natural history study about Amish nemaline myopathy in the Old Order Amish population focuses on the promise of gene therapy for this lethal disorder.
› Verified 7 days ago
Dr. Linda Fong, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 6041 Cadillac Ave, Los Angeles, CA 90034 Phone: 323-857-3290 | |
Dr. Robert Peter Gale, Pulmonary Disease Medicare: Medicare Enrolled Practice Location: 11693 San Vicente Blvd, Suite 335, Los Angeles, CA 90049 Phone: 310-442-9010 | |
Dr. Tarek Alasil, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8616 La Tijera Blvd Ste 404, Los Angeles, CA 90045 Phone: 310-673-2020 Fax: 310-469-5290 | |
David Michael Tellalian, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 8635 W 3rd St Ste 465w, Los Angeles, CA 90048 Phone: 310-358-2300 Fax: 310-358-2308 | |
Dr. Jan B King, M.D., M.P.H. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 11833 Wilmington Ave Fl 2, Los Angeles, CA 90059 Phone: 323-568-8701 | |
Dr. Caroline Hwang, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 1520 San Pablo St, Suite 1000, Los Angeles, CA 90033 Phone: 323-442-5100 | |
Dr. Jennifer A Fulcher, M.D., PH.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 10833 Le Conte Ave, Chs 37-121, Los Angeles, CA 90095 Phone: 310-825-7225 |